Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275754 | 0.88 | ERN1 (0.39) | ERN1CA12CA1CA9ALDH1A1 | |
| SCHEMBL1070012 | 0.84 | CA12 (0.48) | ERN1CA12CA1CA9ALDH1A1 | |
| SCHEMBL28500163 | 0.83 | PTGDR2 (0.48) | ERN1CA12CA1CA9ALDH1A1 | |
| SCHEMBL274474 | 0.81 | ALDH1A1 (0.38) | ERN1CA12CA1CA9ALDH1A1 | |
| SCHEMBL3510807 | 0.81 | MAPT (0.39) | CA12CA1CA9ALDH1A1KDM4E | |
| SCHEMBL4580138 | 0.81 | CA12 (0.33) | CA12CA1CA9ALDH1A1KDM4E | |
| SCHEMBL7263728 | 0.81 | ERN1 (0.37) | ERN1CA12CA1CA9ALDH1A1 | |
| SCHEMBL22032601 | 0.81 | ALDH1A1 (0.40) | ERN1ALDH1A1KDM4EDRD2 | |
| SCHEMBL278950 | 0.81 | ERN1 (0.42) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL23263 | 0.80 | ALDH1A1 (0.50) | ERN1CA12CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | ERN1 2608/4885CA12 4093/4885CA1 3992/4885 |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | ERN1 974/4885CA12 4435/4885CA1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.